Expanding the role of the infection control professional in the cost- effective use of antibiotics

American Journal of Infection Control

Volumn 28, Issue 1, 2000, Pages 57-65

  Minooee, Arézou ^a   Rickman, Leland S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULARY; DRUG MISUSE; DRUG MONITORING; DRUG UTILIZATION; EDUCATION PROGRAM; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; INFECTION CONTROL; INFORMATION SYSTEM; LABORATORY PERSONNEL; PHARMACIST; PHYSICIAN; POLICY; PRESCRIPTION; REVIEW; UNITED STATES; UNIVERSITY HOSPITAL;

EID: 0034006434     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-6553(00)90013-0     Document Type: Article

References (50)

1. Castle M, Wilfert CM, Cate TR, Osterhout S. Antibiotic use at a Duke University Medical Center. JAMA 1977;237:2819-22.
2. Kunin CM, Tupasi T, Craig WA. Use of antibiotics: a brief exposition of the problem and some tentative solutions. Ann Intern Med 1973;79:555-60.
3. Stevens GP, Jacobson JA, Burke JP. Changing patterns of hospital infections and antibiotic use. Arch Intern Med 1981;141:587-92.
4. Ena J. Optimal use of antibiotics. In: Wenzel PP, editor. Prevention and control of nosocomial infections. 3rd ed. Baltimore: Williams & Wilkins; 1997.
5. Polk R. Optimal use of modern antibiotics: emerging trends. Clin Infect Dis 1999;29:264-74.
6. John JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-85.
7. Burke JD, Ahkee S, Ritter GW, Ramirez JA. Development of an interdisciplinary antimicrobial team: elements for success. Hosp Pharm 1996;31:361-6.
8. Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Disease Society of America. J Infect Dis 1988;157:869-76.
9. Garibaldi RA, Burke J. Surveillance and control of antibiotic use in the hospital. Am J Infect Control 1991;19:164-70.
10. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995;155:1949-56.
11. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF, et al. A computer-assisted management program for antibiotics and other anti-infective agents. N Eng J Med 1998;338:232-8.
12. Evans SR, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP. Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994;154:878-84.
13. Parr MD, Hansen LA, Waite WW, Rapp RP. Computer program for comparing total costs of intravenous antibiotic regimens. Am J Hosp Pharm 1986;43:2189-93.
14. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Am Coll Phys 1996;124:884-90.
15. Schentag JJ, Carr JR, Adelman MH, Birmingham MC, Paladino JA, Zimmer G, et al. Formulary management vs. disease management. Infect Dis Clin Prac 1996;5(1 Suppl):S42-S47.
16. Mu-Chow KJ, Rich DS. Developing a successful strategy for controlling inappropriate antibiotic use and cost. Top Hosp Pharm Manage 1988;8:1-21.
17. Robinson A. Rationale for cost-effective laboratory medicine. Am Soc Micro 1994;7:185-99.
18. Parrino TA. The nonvalue of retrospective peer comparison feedback in containing hospital antibiotic costs. Am J Med 1989;86:442-7.
19. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;24:230-9.
20. Eckert DG. Antimicrobial monitoring and evaluation. Am J Infect Control 1989;17:295-9.
21. Otten JE. The changing role of the infection control practitioner. Am J Infect Control 1989;17:62-5.
22. Guglielmo BJ, Brooks GF. Antimicrobial therapy: cost-benefit considerations. Drugs 1989;38:473-80.
23. Quintiliani R, Nightingale CH. Antimicrobials and therapeutic-decision making: an historical perspective. Pharmacotherapy 1991;11:6S-13S.
24. Bakst A. Pharmacoeconomics and the formulary decision-making process. Hosp Form 1995;30:42-50.
25. Davey P. Pharmacoeconomics of appropriate antimicrobial use. Diagn Microbiol Infect Dis 1995;22:225-9.
26. Lacy MK, Eidem LA, Bond JA, Swartz MA. Methods of documenting cost savings associated with an antibiotic management program. Pharm Pract Manage Q 1996;16:66-70.
27. Letizia C. Pharmacoeconomics: an emerging discipline. Quality Assurance, Good Practice, Regulation, and Law 1995;4:68-74.
28. Skaer TL. Applying pharmacoeconomic and quality-of-life measures to the formulary management process. Hosp Form 1993;28:577-84.
29. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157:1132-6.
30. Fletcher C, Giese R, Rodman J. Pharmacist interventions to improve prescribing of vancomycin and tobramycin. Am J Hosp Pharm 1986;43:2198-210.
31. Frighetto L, Nickoloff D, Jewesson P. Antibiotic therapeutic interchange program: six years of experience. Hosp Form 1995;30:92-105.
32. Jackson MM. Epidemiology: expanding applications. Am J Infect Control 1986;14:281-90.
33. Fishman NO, Brennan PJ. Optimizing use of antimicrobial agents: pitfalls and consequences of inappropriate therapy. JCOM 1997;4:25-33.
34. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996;275:234-40.
35. Moellering RC. Past, present, and future of antimicrobial agents. Am J Med 1995;99:11S-18S.
36. Wiedemann B. An international perspective on antimicrobial resistance. Am J Med 1995;99 (Suppl 6A):19S-25S.
37. Moleski RJ, Andriole VT. Role of the infectious disease specialist in containing costs of antibiotics in the hospital. Rev Infect Dis 1986;8:488-93.
38. Polk RE. The role of the infectious diseases physician in monitoring antimicrobial use: a pharmacy perspective. Bull N Y Acad Med 1987;63:612-26.
39. Tice AD, Slama TG, Berman S, Braun P, Burke JP, Cherney A, et al. Managed care and the infectious diseases specialist. Clin Infect Dis 1996;23:341-68.
40. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999;29:60-6.
41. Pierpaoli PG. The risking cost of pharmaceuticals: a director of pharmacy's perspective. Am J Hosp Pharm 1993;50:S6-S8.
42. Pastel DA, Chang S, Nessim S, Shane R, Morgan MA. Department of pharmacy-initiated program for streamlining empirical antibiotic therapy. Hosp Pharm 1992;27:596-603.
43. Witte KW, Nelson AA, Hutchinson RA. Effect of pharmacist consultation on rational antimicrobial therapy. Am J Hosp Pharm 1980;37:829-31.
44. Walley T, Davey P. Pharmacoeconomics: a challenge for clinical pharmacologists. Br J Clin Pharmacol 1995;40:199-202.
45. Capers CC, Bess DT, Branam AC, Falbe WJ, Mrochek SA, Haymond JD, et al. Antibiotic surveillance: the results of a clinical pharmacy intervention program. Hosp Pharm 1993;28:206-11.
46. Albertson T, Musallam N, Tharratt RS, Romac D, Foulke G, Mowers R, et al. Initiation of a clinical pharmacology consult service as a formulary management tool. Hosp Form 1993;28: 699-707.
47. Goff D, Thornton J. Pharmacy-laboratory interactions: a unique method to control antibiotic costs. Hosp Pharm 1989;24:26-30.
48. Lee J, Carlson JA, Chamberlain MA. A team approach to hospital formulary replacement. Diagn Microbiol Infect Dis 1995;22:239-42.
49. Hess DA, Mahoney CD, Johnson PN, Corrao WM, Fisher AE. Integration of clinical and administrative strategies to reduce expenditures for antimicrobial agents. Am J Hosp Pharm 1990;47:585-91.
50. Schentag JJ, Ballow CH, Fritz AL, Paladino JA, Williams JD, Cumbo TJ, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255-64.